Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
about
Evolving immunotherapeutic strategies in bladder and renal cancerPreparation and in-vitro bioactivity of a novel superantigen conjugate targeting bladder carcinoma.System analysis of the regulation of the immune response by CD147 and FOXC1 in cancer cell lines.CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid CancersEGFR may participate in immune evasion through regulation of B7‑H5 expression in non‑small cell lung carcinoma
P2860
Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Bladder cancer immunogenicity: ...... 4+ T cell activation in vitro.
@en
type
label
Bladder cancer immunogenicity: ...... 4+ T cell activation in vitro.
@en
prefLabel
Bladder cancer immunogenicity: ...... 4+ T cell activation in vitro.
@en
P2093
P2860
P1476
Bladder cancer immunogenicity: ...... D4+ T cell activation in vitro
@en
P2093
E O'Flaherty
S J Pettit
T R Griffiths
P2860
P356
10.1046/J.1365-2249.1999.00857.X
P577
1999-04-01T00:00:00Z